As shown in Table 3, IDH1 mutants were observed in 23 (60.5%) of the 38 MGMT promoter-methylated glioma cases compared with wild-type 15 (39.5%), while six (27.3%) IDH1 mutants were found in 22 unmethylated cases versus 16 (72.7%) wild-type cases. Here, IDH1 is linked to central nervous system cancer.